1. Direct and Indirect Costs of Influenza-Like Illness Treated with and Without Oseltamivir in 15 European Countries:A Descriptive Analysis Alongside the Randomised Controlled ALIC(4)E Trial
- Author
-
Nick A Francis, Christopher C Butler, Philippe Beutels, Réka Mikó-Pauer, Ana García-Sangenís, Nikolaos Tsakountakis, Pär-Daniel Sundvall, Katarzyna Kosiek, Joke Bilcke, Rune Aabenhus, Emily Bongard, Ruta Radzeviciene Jurgute, Nicolay Jonassen Harbin, Samuel Coenen, Alike W van der Velden, Xiao Li, Bohumil Seifert, Pascale Bruno, Robin Bruyndonckx, Dominik Glinz, Li, X, Bilcke, J, van der Velden, AW, Bongard, E, BRUYNDONCKX, Robin, Sundvall, PD, Harbin, NJ, Coenen, S, Francis, N, Bruno, P, Garcia-Sangenis, A, Glinz, D, Kosiek, K, Miko-Pauer, R, Jurgute, RR, Seifert, B, Tsakountakis, N, Aabenhus, R, Butler, CC, and Beutels, P
- Subjects
Oseltamivir ,medicine.medical_specialty ,Cost-Benefit Analysis ,Pharmacy ,Antiviral Agents ,law.invention ,chemistry.chemical_compound ,Indirect costs ,Pharmacotherapy ,Randomized controlled trial ,law ,Health care ,Influenza, Human ,medicine ,Humans ,Pharmacology (medical) ,Original Research Article ,Disease burden ,Influenza-like illness ,business.industry ,Pharmacology. Therapy ,virus diseases ,General Medicine ,CARE ,respiratory tract diseases ,Europe ,chemistry ,Emergency medicine ,business ,HEALTHY-ADULTS - Abstract
Background and Objective Influenza-like illness (ILI) leads to a substantial disease burden every winter in Europe; however, oseltamivir is not frequently prescribed to ILI patients in the primary-care setting. An open-label, multi-country, multi-season, randomised controlled trial investigated the effectiveness of oseltamivir for treating ILI in 15 European countries. We aimed to evaluate whether patients presenting with ILI in primary care and being managed with the addition of oseltamivir to usual care had lower average direct and indirect costs compared to patients with usual care alone. Methods Resource use data were extracted from participants' daily diaries. Itemised country-specific unit costs were collected through official tariffs, pharmacies or literature. Costs were converted to 2018 values. The null hypothesis was tested based on one-sided credible intervals (CrIs) obtained by bootstrapping. Base-case analysis estimated direct cost and productivity losses using itemised costed resource use and the human capital approach. Scenario analyses with self-reported spending rather than itemised costing were also performed. Results Patients receiving oseltamivir (N = 1306) reported fewer healthcare visits, medication uses, hospital attendances and paid-work hours lost than the other patients (N = 1298). Excluding the oseltamivir cost, the average direct costs were lower in patients treated with oseltamivir from all perspectives, but these differences were not statistically significant (perspective of patient: euro17 [0-95% Crl: 16-19] vs. euro24 [5-100% Crl: 18-29]; healthcare provider: euro37 [28-67] vs. euro44 [25-55]; healthcare payers: euro54 [45-85] vs. euro68 [45-81]; and society: euro423 [399-478] vs. euro451 [390-478]). Scenario and age-group analyses confirmed these findings, but with some between-country differences. Conclusion The average direct and indirect costs were consistently lower in patients treated with oseltamivir than in patients without from four perspectives (excluding the oseltamivir cost). However, these differences were not statistically significant. The ALIC4E trial and the contributions of AWV, EB, SC, NF, PS, NJH, PaB, AGS, DG, KK, RMP, RRJ, BS, NT, RA, CCB and PB were funded by the European Commission’s Seventh Framework Programme: Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE) (grant HEALTH-F3-2013-602525). PB, XL, JB and RB acknowledge partial Methusalem funding from the VAXIDEA and ASCID Centres of Excellence in vaccination and infectious diseases at the University of Antwerp. JB and RB were funded by their personal postdoctoral grants from the Research Foundation—Flanders (FWO). PS acknowledges that The Healthcare Committee, Region Västra Götaland, Sweden, partially funded the Swedish part of the study.
- Published
- 2021
- Full Text
- View/download PDF